stoxline Quote Chart Rank Option Currency Glossary
  
Cara Therapeutics, Inc. (CARA)
5.2  -0.4 (-7.14%)    02-14 16:00
Open: 5.55
High: 5.55
Volume: 22,623
  
Pre. Close: 5.6
Low: 5.18
Market Cap: 24(M)
Technical analysis
2025-02-14 4:46:54 PM
Short term     
Mid term     
Targets 6-month :  7 1-year :  8.18
Resists First :  6 Second :  7
Pivot price 5.07
Supports First :  4.94 Second :  4.3
MAs MA(5) :  5.24 MA(20) :  5.06
MA(100) :  4.03 MA(250) :  5.74
MACD MACD :  0.1 Signal :  0.1
%K %D K(14,3) :  52 D(3) :  47.5
RSI RSI(14): 53.9
52-week High :  13.8 Low :  2.71
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ CARA ] has closed below upper band by 35.9%. Bollinger Bands are 37.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 5.55 - 5.58 5.58 - 5.6
Low: 5.12 - 5.15 5.15 - 5.17
Close: 5.15 - 5.2 5.2 - 5.24
Company Description

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

Headline News

Thu, 13 Feb 2025
(CARA) Investment Analysis - Stock Traders Daily

Thu, 06 Feb 2025
Cara Therapeutics CEO Christopher Posner sells $1,755 in stock - Investing.com

Mon, 06 Jan 2025
CARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cara Therapeutics, Inc. - CARA - Business Wire

Mon, 30 Dec 2024
Cara Therapeutics announces effective date for 1-for-12 reverse stock split - Hartford Business Journal

Fri, 27 Dec 2024
Cara Therapeutics (CARA) Announces 1-for-12 Reverse Stock Split to Maintain Nasdaq Listing - StockTitan

Wed, 18 Dec 2024
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Cara Therapeutics, Inc. - CARA - PR Newswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 5 (M)
Held by Insiders 4.678e+007 (%)
Held by Institutions 15.7 (%)
Shares Short 832 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.0472e+008
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -1 %
Return on Assets (ttm) 636.1 %
Return on Equity (ttm) -63.5 %
Qtrly Rev. Growth 1.1e+007 %
Gross Profit (p.s.) -126.03
Sales Per Share -271.06
EBITDA (p.s.) -1.14485e+008
Qtrly Earnings Growth -21 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -80 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.02
Price to Cash Flow 3.36
Stock Dividends
Dividend 0
Forward Dividend 942530
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android